Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
SMI 10'268 1.4%  SPI 13'166 1.5%  Dow 28'726 -1.7%  DAX 12'114 1.2%  Euro 0.9672 1.0%  EStoxx50 3'318 1.2%  Gold 1'661 0.0%  Bitcoin 19'178 0.6%  Dollar 0.9886 0.1%  Öl 87.9 -1.1% 
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
17.08.2022 08:00:18

DGAP-News: Gerresheimer AG: Gerresheimer and Zollner enter into a strategic partnership for electronically controlled medtech systems from a single source

DGAP-News: Gerresheimer AG / Key word(s): Alliance
Gerresheimer AG: Gerresheimer and Zollner enter into a strategic partnership for electronically controlled medtech systems from a single source

17.08.2022 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Gerresheimer and Zollner enter into a strategic partnership for electronically controlled medtech systems from a single source

  • Pharma customers gain access to both companies integrated design, development and manufacturing expertise
  • Gerresheimer serves as central point of contact
  • Gerresheimer and Zollner tap into growing demand for digital and connected drug delivery and diagnostic systems 

Düsseldorf /Zandt, August 17, 2022. Gerresheimer AG and Zollner Elektronik AG are pooling their market-leading pharmaceutical and medical technology expertise under a strategic partnership. Starting immediately, they will offer pharmaceutical, healthcare and biotech companies their conceptual design, development and manufacturing capacities for drug delivery and medical technology systems, including complete electronics, from one single source. Gerresheimer serves as the central point of contact for customers. The market-leading partners combine the expertise of Gerresheimer in innovative devices for the administration of medicines and medical technology systems with the globally established electronics expertise of Zollner. Together they want to further develop their expertise in the healthcare sector and open up new markets.

With this strategic partnership, Gerresheimer and Zollner are counting on the global trend toward electronic, digitally controllable and connected drug delivery and diagnostic systems. These include insulin pens, inhalators, like for people suffering with asthma, Point-of-Care systems and medicine pumps. The demand for medical and pharmaceutical devices with electronic components mostly for the treatment of chronic illnesses will significantly increase in coming years. According to studies, the market for digital and connected solutions for the treatment of diabetes alone is expected to grow to around EUR 11bn by 2025.

Zollner Elektronik AG is one of the worlds largest manufacturing service providers for electronic and mechatronic components (Electronic Manufacturing Services or EMS). It generated revenues of around 1.9 billion Euros with just over 12,000 employees at 23 locations in Germany and abroad, 18.3% of that in the area of Healthcare & Life Sciences.

The future belongs to digital treatment support with electronic systems and connected platforms, said Dietmar Siemssen, CEO of Gerresheimer AG. The partnership with Zollner helps us provide our pharma customers with innovative one-stop medtech solutions. For patients, using these solutions means better treatment and enhanced quality of life. At the same time, the healthcare system also benefits by way of permanently reduced treatment costs. 

Digitalization of medical devices is advancing at a very fast tempo. At Zollner, we are happy to have found an ideal partner in Gerresheimer for the expansion of our successful Healthcare & Life Sciences efforts, says Markus Aschenbrenner, Managing Board Member at Zollner. Together we will expand access to existing markets, exploit new growth markets and support our mutual customers along the entire life cycle of the products.

Zollner and Gerresheimer have collected much cooperation experience in numerous projects. The electronics specialist in Zandt already supplies Duesseldorf-based Gerresheimer with components and assemblies for medicine pumps in Parkinsons therapy. Gerresheimer and Zollner are now further developing this cooperation and will act as equal partners for the healthcare system of the future. Through the integration of concept design, development and manufacturing, the products of both sides can be brought to market faster and more efficiently. Also gained is permanent, secure access to electronic components. The cooperation initially covers the development of inhalers for chronic lung disease sufferers, autoinjectors, ophthalmology systems and drug pumps, as well as contract manufacturing for these and similar devices.

Gerresheimer already boasts a portfolio of electronically controlled devices and solutions based on its own intellectual property, including the Respimetrix inhaler and the SensAir pump.The strategic partnership with Zollner will contribute to the significant expansion of that portfolio.

This partnership also supports the sustainability strategies of both companies. For instance, they have agreed on a technology exchange enabling the development of even more efficient production processes including with the use of artificial intelligence to minimize waste and rejects.
 

Press Contact (Gerresheimer AG)
Ueli Utzinger 
Group Senior Director of Communication & Marketing
T +41 79 400 86 40
ueli.utzinger@gerresheimer.com

Investor Relations Contact (Gerresheimer AG)
Carolin Nadilo
Corporate Senior Director of Investor Relations
T +49 211 6181-220
carolin.nadilo@gerresheimer.com

Press Contact (Zollner Elektronik AG)
Siegfried Weinberger
Director of Sales Healthcare & Life Sciences
T + 49 9944 201-3384
siegfried_weinberger@zollner.de

About Gerresheimer
Gerresheimer is the global partner for pharmaceuticals, biotech, health and cosmetics with a very broad product spectrum for medicine and cosmetic packaging as well as drug delivery devices. The company offers innovative solutions, from the concept to delivery of the end product. Gerresheimer achieves its ambitious goals with high level of innovative power, industrial expertise and concentration on quality and customer focus. In the development of innovative and sustainable solutions, Gerresheimer places its faith in a comprehensive, international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers with around 11,000 employees and generates an annual revenue of approximately 1.5 billion Euros. With its products and solutions, Gerresheimer plays a significant role for the health and well-being of mankind.

About Zollner
The family-owned company with its headquarters in Zandt is Europes market leader in the Electronics Manufacturing Services sector. Founded in 1965, it has grown organically to become a global player with around 12,000 employees and 23 locations around the globe. Zollner Elektronik AG is one of the three largest solution providers in Europe in the Healthcare & Life Sciences sector and belongs in the top ten globally with more than two decades of experience with highly complex medical technology products. Its services encompass the complete product life cycle and cover segments of Medical Technology, Pharmaceutical Devices, Laboratory Equipment and Digital Health - the ideal prerequisites for supporting the transformation and technological progress in the area of Healthcare & Life Sciences.



17.08.2022 CET/CEST Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Gerresheimer AG
Klaus-Bungert-Str. 4
40468 Düsseldorf
Germany
Phone: +49-(0)211/61 81-314
Fax: +49-(0)211/61 81-121
E-mail: carolin.nadilo@gerresheimer.com
Internet: http://www.gerresheimer.com
ISIN: DE000A0LD6E6
WKN: A0LD6E
Indices: MDAX (Aktie)
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1421845

 
End of News DGAP News Service

1421845  17.08.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1421845&application_name=news&site_id=smarthouse

INFLATION: WELTWEIT STEIGEN DIE PREISE

Viele Anleger setzen deshalb auf den Aktiv verwalteten Global Inflation Protection Basket. Informieren Sie sich über die breit gestreute Auswahl an robusten Aktien & ETFs.


Analysen zu Gerresheimer AG

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
21.09.22 Gerresheimer Neutral JP Morgan Chase & Co.
19.08.22 Gerresheimer Neutral JP Morgan Chase & Co.
10.08.22 Gerresheimer Buy Deutsche Bank AG
14.07.22 Gerresheimer Outperform Credit Suisse Group
14.07.22 Gerresheimer Buy Deutsche Bank AG

Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 10'696.56 17.37 3SSMFU
Short 10'900.85 12.89 2SSMSU
Short 11'261.87 8.83 USSMMU
SMI-Kurs: 10'267.55 30.09.2022 17:31:51
Long 9'762.57 16.94 S2BMIU
Long 9'599.92 13.39 VSSMDU
Long 9'168.80 8.61 SMIFIU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}